STOCK TITAN

[S-8 POS] Inozyme Pharma, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
S-8 POS
Rhea-AI Filing Summary

Everi Holdings Inc. (EVRI) has filed Form 25 with the U.S. Securities and Exchange Commission, notifying the SEC and investors that its common stock is being removed from listing and registration on the New York Stock Exchange (NYSE) pursuant to Section 12(b) of the Securities Exchange Act of 1934.

The filing, signed on 1 July 2025 by NYSE representative Tyler Mastronardi, certifies that the Exchange has satisfied all applicable rules under 17 CFR 240.12d2-2(b) for striking the security from listing. No financial statements, earnings data, or explanatory detail regarding the cause of delisting are provided in the document.

  • Issuer: Everi Holdings Inc., 7250 S. Tenaya Way, Suite 100, Las Vegas, NV 89113; Tel: (702) 855-3006
  • Security affected: Common Stock
  • Exchange: New York Stock Exchange LLC
  • Action: Removal from listing and/or registration under Rule 12d2-2

The notice indicates either the NYSE or the company (or both) initiated the delisting process in accordance with Exchange and SEC rules, but the form does not specify the underlying reason, effective date, or post-delisting trading venue.

Everi Holdings Inc. (EVRI) ha presentato il Modulo 25 presso la U.S. Securities and Exchange Commission, informando la SEC e gli investitori che le sue azioni ordinarie saranno rimosse dalla quotazione e registrazione al New York Stock Exchange (NYSE) ai sensi della Sezione 12(b) del Securities Exchange Act del 1934.

La presentazione, firmata il 1 luglio 2025 dal rappresentante del NYSE Tyler Mastronardi, certifica che la Borsa ha rispettato tutte le norme applicabili secondo il 17 CFR 240.12d2-2(b) per la rimozione del titolo dalla quotazione. Nel documento non sono forniti bilanci, dati sugli utili o dettagli esplicativi riguardo la causa della delisting.

  • Emittente: Everi Holdings Inc., 7250 S. Tenaya Way, Suite 100, Las Vegas, NV 89113; Tel: (702) 855-3006
  • Titolo interessato: Azioni ordinarie
  • Borsa: New York Stock Exchange LLC
  • Azione: Rimozione dalla quotazione e/o registrazione secondo la Regola 12d2-2

La notifica indica che il processo di delisting è stato avviato dal NYSE o dalla società (o da entrambi) in conformità con le regole della Borsa e della SEC, ma il modulo non specifica la motivazione sottostante, la data di efficacia o il mercato di negoziazione dopo la delisting.

Everi Holdings Inc. (EVRI) ha presentado el Formulario 25 ante la Comisión de Bolsa y Valores de EE.UU., notificando a la SEC y a los inversores que sus acciones comunes serán retiradas de la cotización y registro en la Bolsa de Valores de Nueva York (NYSE) conforme a la Sección 12(b) de la Ley de Intercambio de Valores de 1934.

La presentación, firmada el 1 de julio de 2025 por el representante del NYSE Tyler Mastronardi, certifica que la Bolsa ha cumplido con todas las reglas aplicables bajo el 17 CFR 240.12d2-2(b) para retirar el valor de la cotización. El documento no incluye estados financieros, datos de ganancias ni detalles explicativos sobre la causa de la exclusión.

  • Emisor: Everi Holdings Inc., 7250 S. Tenaya Way, Suite 100, Las Vegas, NV 89113; Tel: (702) 855-3006
  • Valor afectado: Acciones comunes
  • Bolsa: New York Stock Exchange LLC
  • Acción: Retiro de cotización y/o registro bajo la Regla 12d2-2

El aviso indica que el proceso de exclusión fue iniciado por el NYSE o la empresa (o ambos) conforme a las reglas de la Bolsa y la SEC, pero el formulario no especifica la razón subyacente, la fecha efectiva ni el mercado de negociación posterior a la exclusión.

Everi Holdings Inc. (EVRI)는 미국 증권거래위원회(SEC)에 Form 25를 제출하여, 자사의 보통주가 1934년 증권거래법 12(b)조에 따라 뉴욕증권거래소(NYSE)에서 상장 및 등록이 취소될 것임을 SEC와 투자자에게 통지했습니다.

2025년 7월 1일, NYSE 대표 Tyler Mastronardi가 서명한 이 서류는 거래소가 상장 취소를 위한 17 CFR 240.12d2-2(b) 규정을 모두 준수했음을 인증합니다. 문서에는 재무제표, 수익 데이터 또는 상장 취소 사유에 대한 설명이 포함되어 있지 않습니다.

  • 발행인: Everi Holdings Inc., 7250 S. Tenaya Way, Suite 100, Las Vegas, NV 89113; 전화: (702) 855-3006
  • 해당 증권: 보통주
  • 거래소: 뉴욕증권거래소 LLC
  • 조치: 규칙 12d2-2에 따른 상장 및/또는 등록 취소

이 통지는 NYSE 또는 회사(또는 양측)가 거래소 및 SEC 규정에 따라 상장 취소 절차를 시작했음을 나타내지만, 서류에는 근본적인 이유, 효력 발생일 또는 상장 취소 후 거래 장소가 명시되어 있지 않습니다.

Everi Holdings Inc. (EVRI) a déposé le formulaire 25 auprès de la Securities and Exchange Commission des États-Unis, informant la SEC et les investisseurs que ses actions ordinaires seront retirées de la cotation et de l'enregistrement à la Bourse de New York (NYSE) conformément à la section 12(b) du Securities Exchange Act de 1934.

Le dépôt, signé le 1er juillet 2025 par le représentant du NYSE Tyler Mastronardi, certifie que la Bourse a respecté toutes les règles applicables en vertu du 17 CFR 240.12d2-2(b) pour le retrait de la valeur de la cotation. Le document ne fournit ni états financiers, ni données sur les bénéfices, ni détails explicatifs concernant la cause du retrait.

  • Émetteur : Everi Holdings Inc., 7250 S. Tenaya Way, Suite 100, Las Vegas, NV 89113 ; Tél. : (702) 855-3006
  • Valeur concernée : Actions ordinaires
  • Bourse : New York Stock Exchange LLC
  • Action : Retrait de la cotation et/ou de l'enregistrement selon la règle 12d2-2

L'avis indique que le processus de retrait a été initié par le NYSE ou la société (ou les deux) conformément aux règles de la Bourse et de la SEC, mais le formulaire ne précise pas la raison sous-jacente, la date d'effet ni le lieu de négociation après le retrait.

Everi Holdings Inc. (EVRI) hat bei der US-Börsenaufsichtsbehörde SEC das Formular 25 eingereicht und die SEC sowie Investoren darüber informiert, dass die Stammaktien des Unternehmens gemäß Abschnitt 12(b) des Securities Exchange Act von 1934 von der Notierung und Registrierung an der New Yorker Börse (NYSE) entfernt werden.

Die Einreichung, unterzeichnet am 1. Juli 2025 vom NYSE-Vertreter Tyler Mastronardi, bestätigt, dass die Börse alle geltenden Vorschriften gemäß 17 CFR 240.12d2-2(b) für die Streichung des Wertpapiers aus der Notierung erfüllt hat. Im Dokument werden keine Finanzberichte, Gewinnzahlen oder erläuternde Details zum Delisting-Grund angegeben.

  • Emittent: Everi Holdings Inc., 7250 S. Tenaya Way, Suite 100, Las Vegas, NV 89113; Tel.: (702) 855-3006
  • Betroffenes Wertpapier: Stammaktien
  • Börse: New York Stock Exchange LLC
  • Maßnahme: Entfernung von der Notierung und/oder Registrierung gemäß Regel 12d2-2

Die Mitteilung weist darauf hin, dass der Delisting-Prozess entweder von der NYSE oder dem Unternehmen (oder beiden) gemäß den Regeln der Börse und der SEC eingeleitet wurde, jedoch nennt das Formular keinen zugrundeliegenden Grund, kein Wirksamkeitsdatum oder den Handelsplatz nach dem Delisting.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: EVRI is being delisted from the NYSE; liquidity and visibility risks rise.

The Form 25 filing is a definitive step toward terminating EVRI’s NYSE listing and Section 12(b) registration. From an investor standpoint, delisting can materially reduce share liquidity, narrow the investor base, and often precedes migration to OTC trading or a corporate transaction. Because the filing lacks context—no mention of mergers, going-private plans, or compliance failures—uncertainty remains high. Nonetheless, the imminent loss of a primary exchange listing is typically viewed as negative for valuation and governance transparency.

TL;DR: Formal notice confirms regulatory compliance but offers no rationale.

By filing under Rule 12d2-2, the NYSE affirms procedural compliance, limiting legal exposure for both the Exchange and the issuer. However, absence of explanatory disclosure deprives shareholders of material context required for informed voting or exit decisions. Governance best practices would normally call for a concurrent press release or 8-K. The lack of such detail could raise transparency concerns.

Everi Holdings Inc. (EVRI) ha presentato il Modulo 25 presso la U.S. Securities and Exchange Commission, informando la SEC e gli investitori che le sue azioni ordinarie saranno rimosse dalla quotazione e registrazione al New York Stock Exchange (NYSE) ai sensi della Sezione 12(b) del Securities Exchange Act del 1934.

La presentazione, firmata il 1 luglio 2025 dal rappresentante del NYSE Tyler Mastronardi, certifica che la Borsa ha rispettato tutte le norme applicabili secondo il 17 CFR 240.12d2-2(b) per la rimozione del titolo dalla quotazione. Nel documento non sono forniti bilanci, dati sugli utili o dettagli esplicativi riguardo la causa della delisting.

  • Emittente: Everi Holdings Inc., 7250 S. Tenaya Way, Suite 100, Las Vegas, NV 89113; Tel: (702) 855-3006
  • Titolo interessato: Azioni ordinarie
  • Borsa: New York Stock Exchange LLC
  • Azione: Rimozione dalla quotazione e/o registrazione secondo la Regola 12d2-2

La notifica indica che il processo di delisting è stato avviato dal NYSE o dalla società (o da entrambi) in conformità con le regole della Borsa e della SEC, ma il modulo non specifica la motivazione sottostante, la data di efficacia o il mercato di negoziazione dopo la delisting.

Everi Holdings Inc. (EVRI) ha presentado el Formulario 25 ante la Comisión de Bolsa y Valores de EE.UU., notificando a la SEC y a los inversores que sus acciones comunes serán retiradas de la cotización y registro en la Bolsa de Valores de Nueva York (NYSE) conforme a la Sección 12(b) de la Ley de Intercambio de Valores de 1934.

La presentación, firmada el 1 de julio de 2025 por el representante del NYSE Tyler Mastronardi, certifica que la Bolsa ha cumplido con todas las reglas aplicables bajo el 17 CFR 240.12d2-2(b) para retirar el valor de la cotización. El documento no incluye estados financieros, datos de ganancias ni detalles explicativos sobre la causa de la exclusión.

  • Emisor: Everi Holdings Inc., 7250 S. Tenaya Way, Suite 100, Las Vegas, NV 89113; Tel: (702) 855-3006
  • Valor afectado: Acciones comunes
  • Bolsa: New York Stock Exchange LLC
  • Acción: Retiro de cotización y/o registro bajo la Regla 12d2-2

El aviso indica que el proceso de exclusión fue iniciado por el NYSE o la empresa (o ambos) conforme a las reglas de la Bolsa y la SEC, pero el formulario no especifica la razón subyacente, la fecha efectiva ni el mercado de negociación posterior a la exclusión.

Everi Holdings Inc. (EVRI)는 미국 증권거래위원회(SEC)에 Form 25를 제출하여, 자사의 보통주가 1934년 증권거래법 12(b)조에 따라 뉴욕증권거래소(NYSE)에서 상장 및 등록이 취소될 것임을 SEC와 투자자에게 통지했습니다.

2025년 7월 1일, NYSE 대표 Tyler Mastronardi가 서명한 이 서류는 거래소가 상장 취소를 위한 17 CFR 240.12d2-2(b) 규정을 모두 준수했음을 인증합니다. 문서에는 재무제표, 수익 데이터 또는 상장 취소 사유에 대한 설명이 포함되어 있지 않습니다.

  • 발행인: Everi Holdings Inc., 7250 S. Tenaya Way, Suite 100, Las Vegas, NV 89113; 전화: (702) 855-3006
  • 해당 증권: 보통주
  • 거래소: 뉴욕증권거래소 LLC
  • 조치: 규칙 12d2-2에 따른 상장 및/또는 등록 취소

이 통지는 NYSE 또는 회사(또는 양측)가 거래소 및 SEC 규정에 따라 상장 취소 절차를 시작했음을 나타내지만, 서류에는 근본적인 이유, 효력 발생일 또는 상장 취소 후 거래 장소가 명시되어 있지 않습니다.

Everi Holdings Inc. (EVRI) a déposé le formulaire 25 auprès de la Securities and Exchange Commission des États-Unis, informant la SEC et les investisseurs que ses actions ordinaires seront retirées de la cotation et de l'enregistrement à la Bourse de New York (NYSE) conformément à la section 12(b) du Securities Exchange Act de 1934.

Le dépôt, signé le 1er juillet 2025 par le représentant du NYSE Tyler Mastronardi, certifie que la Bourse a respecté toutes les règles applicables en vertu du 17 CFR 240.12d2-2(b) pour le retrait de la valeur de la cotation. Le document ne fournit ni états financiers, ni données sur les bénéfices, ni détails explicatifs concernant la cause du retrait.

  • Émetteur : Everi Holdings Inc., 7250 S. Tenaya Way, Suite 100, Las Vegas, NV 89113 ; Tél. : (702) 855-3006
  • Valeur concernée : Actions ordinaires
  • Bourse : New York Stock Exchange LLC
  • Action : Retrait de la cotation et/ou de l'enregistrement selon la règle 12d2-2

L'avis indique que le processus de retrait a été initié par le NYSE ou la société (ou les deux) conformément aux règles de la Bourse et de la SEC, mais le formulaire ne précise pas la raison sous-jacente, la date d'effet ni le lieu de négociation après le retrait.

Everi Holdings Inc. (EVRI) hat bei der US-Börsenaufsichtsbehörde SEC das Formular 25 eingereicht und die SEC sowie Investoren darüber informiert, dass die Stammaktien des Unternehmens gemäß Abschnitt 12(b) des Securities Exchange Act von 1934 von der Notierung und Registrierung an der New Yorker Börse (NYSE) entfernt werden.

Die Einreichung, unterzeichnet am 1. Juli 2025 vom NYSE-Vertreter Tyler Mastronardi, bestätigt, dass die Börse alle geltenden Vorschriften gemäß 17 CFR 240.12d2-2(b) für die Streichung des Wertpapiers aus der Notierung erfüllt hat. Im Dokument werden keine Finanzberichte, Gewinnzahlen oder erläuternde Details zum Delisting-Grund angegeben.

  • Emittent: Everi Holdings Inc., 7250 S. Tenaya Way, Suite 100, Las Vegas, NV 89113; Tel.: (702) 855-3006
  • Betroffenes Wertpapier: Stammaktien
  • Börse: New York Stock Exchange LLC
  • Maßnahme: Entfernung von der Notierung und/oder Registrierung gemäß Regel 12d2-2

Die Mitteilung weist darauf hin, dass der Delisting-Prozess entweder von der NYSE oder dem Unternehmen (oder beiden) gemäß den Regeln der Börse und der SEC eingeleitet wurde, jedoch nennt das Formular keinen zugrundeliegenden Grund, kein Wirksamkeitsdatum oder den Handelsplatz nach dem Delisting.

As filed with the Securities and Exchange Commission on July 1, 2025

Registration No. 333-240146

Registration No. 333-254685

Registration No. 333-263586

Registration No. 333-270733

Registration No. 333-277839

Registration No. 333-285687

 

 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

POST-EFFECTIVE AMENDMENT NO. 1 TO

FORM S-8 REGISTRATION STATEMENT No. 333-240146

FORM S-8 REGISTRATION STATEMENT No. 333-254685

FORM S-8 REGISTRATION STATEMENT No. 333-263586

FORM S-8 REGISTRATION STATEMENT No. 333-270733

FORM S-8 REGISTRATION STATEMENT No. 333-277839

FORM S-8 REGISTRATION STATEMENT No. 333-285687

UNDER

THE SECURITIES ACT OF 1933

 

 

INOZYME PHARMA, INC.

(Exact Name of Registrant As Specified In Its Charter)

 

 

 

Delaware   38-4024528
(State or other jurisdiction
of incorporation or organization)
  (I.R.S. Employer
Identification No.)

321 Summer Street

Suite 400

Boston, Massachusetts

  02210
(Address of Principal Executive Offices)   (Zip Code)

Amended and Restated 2017 Equity Incentive Plan, as amended

2020 Stock Incentive Plan

2020 Employee Stock Purchase Plan

2023 Inducement Stock Incentive Plan

(Full titles of the plans)

 

 

G. Eric Davis

President

Inozyme Pharma, Inc.

321 Summer Street

Suite 400

Boston, Massachusetts, 02210

(Name and address of agent for service)

(857) 330-4340

(Telephone number, including area code, of agent for service)

Copies to:

Jamie Leigh, Esq.

Ben Beerle, Esq.

Chadwick Mills, Esq.

Siana Lowrey, Esq.

Cooley LLP

3 Embarcadero Center

20th Floor

San Francisco, CA 94111

(415) 693-2000

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer      Accelerated filer  
Non-accelerated filer      Smaller reporting company  
     Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

 

 
 


EXPLANATORY NOTE

This Post-Effective Amendment No. 1 relates to the following Registration Statements on Form S-8 (each a “Registration Statement” and collectively, the “Registration Statements”), filed with the Securities and Exchange Commission (the “SEC”) by Inozyme Pharma, Inc., a Delaware corporation (the “Registrant”) and is being filed to deregister any and all securities that remain unsold or otherwise unissued as of the date hereunder under such Registration Statements:

 

   

Registration Statement No. 333-240146, registering (i) 2,078,405 shares of the Registrant’s common stock, par value $0.0001 per share (“Common Stock”), issuable under the Inozyme Pharma, Inc. Amended and Restated 2017 Equity Incentive Plan, as amended; (ii) 2,014,380 shares of Common Stock issuable under the Inozyme Pharma, Inc. 2020 Stock Incentive Plan (the “2020 Incentive Plan”) and (iii) 198,539 shares of Common Stock issuable under the Inozyme Pharma, Inc. 2020 Employee Stock Purchase Plan (the “ESPP”), filed with the SEC on July 28, 2020;

 

   

Registration Statement No. 333-254685, registering an additional (i) 935,398 shares of Common Stock issuable under the 2020 Incentive Plan and (ii) 233,849 shares of Common Stock issuable under the ESPP filed with the SEC on March 25, 2021;

 

   

Registration Statement No. 333-263586, registering an additional (i) 946,749 shares of Common Stock issuable under the 2020 Incentive Plan and (ii) 236,687 shares of Common Stock issuable under the ESPP, filed with the SEC on March 15, 2022;

 

   

Registration Statement No. 333-270733, registering (i) an additional 1,615,774 shares of Common Stock issuable under the 2020 Incentive Plan; (ii) an additional 397,079 shares of Common Stock issuable under the ESPP and (iii) 1,000,000 shares of Common Stock issuable under the Inozyme Pharma, Inc. 2023 Inducement Stock Incentive Plan filed with the SEC on March 22, 2023;

 

   

Registration Statement No. 333-277839, registering an additional (i) 2,470,750 shares of Common Stock issuable under the 2020 Incentive Plan and (ii) 397,079 shares of Common Stock issuable under the ESPP, filed with the SEC on March 12, 2024; and

 

   

Registration Statement No. 333-285687, registering an additional (i) 2,569,607 shares of Common Stock issuable under the 2020 Incentive Plan and (ii) 397,079 shares of Common Stock issuable under the ESPP, filed with the SEC on March 10, 2025.

On May 16, 2025, the Registrant entered into that certain Agreement and Plan of Merger (the “Merger Agreement”) with BioMarin Pharmaceutical Inc., a Delaware corporation (“Parent”), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (“Merger Sub”). Pursuant to the Merger Agreement, on July 1, 2025, Merger Sub merged with and into the Registrant with the Registrant surviving the merger as a wholly-owned subsidiary of Parent (the “Merger”).

As a result of the Merger, the Registrant has terminated any and all of the offerings and sales of the Registrant’s securities pursuant to the Registration Statements. In accordance with the undertakings made by the Registrant in the Registration Statements to remove from registration, by means of a post-effective amendment, any securities that had been registered for issuance under the Registration Statements but remain unsold at the termination of the offerings, the Registrant hereby removes and withdraws from registration any and all securities registered pursuant to the Registration Statements that remain unsold as of the date hereof, and each Registration Statement is hereby amended, as appropriate, to reflect the deregistration of such securities, and the Registrant hereby terminates the effectiveness of the Registration Statements.


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments No. 1 to the Registration Statements on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Rafael, California, on July 1, 2025.

 

Inozyme Pharma, Inc.

By:   /s/ G. Eric Davis

Name:

 

G. Eric Davis

Title:

 

President

No other person is required to sign these Post-Effective Amendments to the Registration Statements in reliance on Rule 478 of the Securities Act of 1933, as amended.

FAQ

Why did Everi Holdings (EVRI) file Form 25?

Form 25 is required to formally remove EVRI’s common stock from NYSE listing and Section 12(b) registration; no reason is disclosed in the filing.

When was the Form 25 for EVRI signed?

The notification was signed on July 1, 2025 by an authorized NYSE representative.

Which security class is affected by the delisting?

The filing applies to Everi Holdings Inc.’s common stock.

Does the filing mention where EVRI shares will trade after delisting?

No. The document does not specify any post-delisting trading venue such as OTC markets.

What rule governs the removal from listing noted in this filing?

The NYSE cites compliance with 17 CFR 240.12d2-2(b) for striking the security from listing.
Inozyme Pharma, Inc.

NASDAQ:INZY

INZY Rankings

INZY Latest News

INZY Latest SEC Filings

INZY Stock Data

257.60M
63.15M
1.2%
92.62%
6.83%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON